Pharmaceutical companies and lawyers in Brazil are still awaiting the outcome of a consultation run by the drugs regulator ANVISA on plans to allow the use of “skinny labels” on generic medicines to avoid potential patent infringement.
The move would change the regulations so that the labeling of generic medicines could omit any indications of the originator...





